These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24526731)

  • 1. Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.
    Spanheimer PM; Park JM; Askeland RW; Kulak MV; Woodfield GW; De Andrade JP; Cyr AR; Sugg SL; Thomas A; Weigel RJ
    Clin Cancer Res; 2014 Apr; 20(8):2115-25. PubMed ID: 24526731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.
    Spanheimer PM; Cyr AR; Gillum MP; Woodfield GW; Askeland RW; Weigel RJ
    Ann Surg; 2014 Apr; 259(4):793-9. PubMed ID: 24045439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.
    De Andrade JP; Park JM; Gu VW; Woodfield GW; Kulak MV; Lorenzen AW; Wu VT; Van Dorin SE; Spanheimer PM; Weigel RJ
    Mol Cancer Ther; 2016 Mar; 15(3):503-11. PubMed ID: 26832794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
    Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
    Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
    Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
    J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
    Suzuki M; Makinoshima H; Matsumoto S; Suzuki A; Mimaki S; Matsushima K; Yoh K; Goto K; Suzuki Y; Ishii G; Ochiai A; Tsuta K; Shibata T; Kohno T; Esumi H; Tsuchihara K
    Cancer Sci; 2013 Jul; 104(7):896-903. PubMed ID: 23578175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.
    Anbalagan M; Carrier L; Glodowski S; Hangauer D; Shan B; Rowan BG
    Breast Cancer Res Treat; 2012 Apr; 132(2):391-409. PubMed ID: 21509526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
    Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM
    Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Ruffilli I; Elia G; Ragusa F; Fioravanti A; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2306-2314. PubMed ID: 29517106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer.
    Spanheimer PM; Bashir A; Lorenzen AW; Beck AC; Liao J; Lizarraga IM; Erdahl LM; Sugg SL; Karwal MW; Weigel RJ
    Am J Clin Oncol; 2021 Sep; 44(9):456-462. PubMed ID: 34190716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
    Plaza-Menacho I; Morandi A; Robertson D; Pancholi S; Drury S; Dowsett M; Martin LA; Isacke CM
    Oncogene; 2010 Aug; 29(33):4648-57. PubMed ID: 20531297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
    Pancholi S; Lykkesfeldt AE; Hilmi C; Banerjee S; Leary A; Drury S; Johnston S; Dowsett M; Martin LA
    Endocr Relat Cancer; 2008 Dec; 15(4):985-1002. PubMed ID: 18824559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.
    Zhang X; Zhang B; Liu J; Liu J; Li C; Dong W; Fang S; Li M; Song B; Tang B; Wang Z; Zhang Y
    Sci Rep; 2015 Feb; 5():7835. PubMed ID: 25644501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.
    Li H; Pan GF; Jiang ZZ; Yang J; Sun LX; Zhang LY
    Acta Pharmacol Sin; 2015 May; 36(5):606-13. PubMed ID: 25864647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
    Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A
    Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET rearrangements are actionable alterations in breast cancer.
    Paratala BS; Chung JH; Williams CB; Yilmazel B; Petrosky W; Williams K; Schrock AB; Gay LM; Lee E; Dolfi SC; Pham K; Lin S; Yao M; Kulkarni A; DiClemente F; Liu C; Rodriguez-Rodriguez L; Ganesan S; Ross JS; Ali SM; Leyland-Jones B; Hirshfield KM
    Nat Commun; 2018 Nov; 9(1):4821. PubMed ID: 30446652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.
    Liu H; Cheng D; Weichel AK; Osipo C; Wing LK; Chen B; Louis TE; Jordan VC
    Int J Oncol; 2006 Nov; 29(5):1237-46. PubMed ID: 17016657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
    Long X; Fan M; Bigsby RM; Nephew KP
    Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
    Gee JM; Harper ME; Hutcheson IR; Madden TA; Barrow D; Knowlden JM; McClelland RA; Jordan N; Wakeling AE; Nicholson RI
    Endocrinology; 2003 Nov; 144(11):5105-17. PubMed ID: 12960029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.